Phillip Md Et Al Frost Purchases 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock in a transaction dated Friday, January 17th. The shares were purchased at an average cost of $1.47 per share, with a total value of $220,500.00. Following the acquisition, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at approximately $313,384,121.19. This trade represents a 0.07 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was bought at an average price of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The shares were bought at an average price of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The shares were bought at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Performance

NASDAQ:OPK remained flat at $1.47 during trading hours on Friday. The company had a trading volume of 2,564,480 shares, compared to its average volume of 2,888,357. The stock has a fifty day moving average price of $1.55 and a two-hundred day moving average price of $1.50. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76.

Hedge Funds Weigh In On OPKO Health

A number of large investors have recently made changes to their positions in the business. FMR LLC grew its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Algert Global LLC purchased a new position in shares of OPKO Health during the 2nd quarter valued at $44,000. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health in the third quarter worth $45,000. Private Advisor Group LLC raised its holdings in shares of OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 25,000 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in OPKO Health during the third quarter valued at $61,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

OPK has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Wednesday, January 8th. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.